The Journal and Authors retract the 28 January 2016 article cited above for the following reasons: Following online criticisms of the published paper, an investigation at the journal has confirmed the manipulation and duplication of data, and a level of image processing that is not compliant with the journal’s policies on image data integrity.
Further, a post-publication cross-check screening revealed significant overlap with another manuscript submitted by the authors to another journal. While all manuscripts submitted to Frontiers undergo cross-check screening, the article cited below was in review in parallel with the Frontiers article and thus the overlap was not apparent until publication (Samie et al., 2016).
References
1
SamieN.MuniandyS.KanthimathiM. S.HaerianB. S. (2016). Mechanism of action of novel piperazine containing a toxicant against human liver cancer cells. PeerJ.4:e1588. 10.7717/peerj.1588
Summary
Keywords
Apoptosis, cell cycle arrest, Nickel(II) complex, NF-κB, Colon Cancer
Citation
Frontiers in Pharmacology Editorial Office (2016) Retraction: Mechanism of Action of the Novel Nickel(II) Complex in Simultaneous Reactivation of the Apoptotic Signaling Networks Against Human Colon Cancer Cells. Front. Pharmacol. 7:199. doi: 10.3389/fphar.2016.00199
Received
22 June 2016
Accepted
22 June 2016
Published
29 June 2016
Approved by
Théophile Godfraind, Université Catholique de Louvain, Belgium
Volume
7 - 2016
Updates
Copyright
© 2016 Frontiers in Pharmacology Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers in Pharmacology Editorial Office pharmacology.editorial.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.